Global consortium launches new study into long-term effects of COVID-19
14 September 2020
The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC), based at Oxford University, in collaboration with Dr Janet Scott, of the MRC-University of Glasgow’s Centre for Virus Research, has launched a longitudinal observational study to measure prevalence and risk factors of long-term health and psychosocial consequences of COVID-19. The researchers are inviting hospitals and healthcare sites worldwide to join this new study.
Persistent immune memory of COVID-19 found in recovered patient T cells
4 September 2020
Oxford University researchers have found that natural infection with COVID-19 produces a robust T cell response, including inducing T cell ‘memory’ to potentially fight future infections.
Five years at the top: Oxford retains first place in World University Rankings
4 September 2020
Oxford University has topped the THE World University Rankings for a fifth consecutive year.
Development of Oxford COVID-19 vaccine expands into US Phase III clinical trial
4 September 2020
A new arm of the ongoing global clinical trials of the ChAdOx1 nCoV-19 vaccine led by AstraZeneca has launched in the US to assess safety, efficacy and immunogenicity of the vaccine for the prevention of COVID-19.
Four Oxford academics honoured by the Royal Society
5 August 2020
Four researchers from Oxford University have today received prestigious medals and prizes from the Royal Society in recognition of their outstanding contributions to science and medicine.
New study reveals Oxford coronavirus vaccine produces strong immune response
31 July 2020
A team of scientists at Oxford University’s Jenner Institute and Oxford Vaccine Group has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus.
Value of lipocalin 2 as a potential biomarker for bacterial meningitis
24 July 2020
A team from OUCRU led by Le Van Tan, Hospital for Tropical Diseases, Vietnam, and Benedikt Kessler at the Target Discovery Institute at the University of Oxford showed that lipocalin 2 is a sensitive and specific biomarker for discriminating bacterial meningitis from a broad spectrum of other brain infections, and outperforms routine CSF markers such as leukocytes, glucose, protein and lactate.
Dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19
17 June 2020
In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Over 11,500 patients have been enrolled from over 175 NHS hospitals in the UK.
No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19
5 June 2020
A new statement has been released from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine.
Expanding the immune system's arsenal to fend off viruses and cancer cells
13 May 2020
Cytotoxic T lymphocytes (CTLs) kill infected and cancerous cells. Mike Dustin's team at the Kennedy Institute of Rheumatology, together with Roman Fischer and Benedikt Kessler from the Target Discovery Institute, NDM, detected transfer of cytotoxic multiprotein complexes from CTLs to target cells, termed supramolecular attack particles (SMAPs). SMAPs were rapidly released from CTLs and were autonomously cytotoxic.
Volunteer for COVID-19 studies at Oxford
12 May 2020
We have a range of studies taking place at the moment, below are listed those that are still open for participants to take part in.
Six Oxford professors honoured by the Royal Society
1 May 2020
Six Oxford University academics have been elected to the prestigious Fellowship of the Royal Society.
Landmark partnership announced for development of COVID-19 vaccine
1 May 2020
The University of Oxford announced yesterday an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University.
Results of remdesivir trial released
1 May 2020
The results of a placebo-controlled trial of remdesivir in COVID-19 patients have been published in the Lancet.
Latest on Oxford's fight against COVID-19
29 April 2020
22 Apr 2020 By Charvy Narain Much has changed since the beginning of the year, when University of Oxford researchers first started coming together to fight the novel coronavirus outbreak. But what has remained consistent is that the University of Oxford remains at the forefront of global efforts to combat the SARS-CoV-2 virus and mitigate its many effects: medical students have been stepping up, researchers with clinical skills are returning to front-line clinical roles, and others are offering up equipment and materials, as well as their laboratory skills to help the NHS respond to the crisis.
Oxford app helps avoid lockdown crowds
29 April 2020
Keep safe, keep your distance – but keep on the go in the lockdown with Crowdless (crowdlessapp.co), a real-time app designed by an Oxford post-graduate student and other young entrepreneurs - and backed by the Oxford venture-supporting Foundry.
Researchers use virus genomic tracking to reveal the rise and fall of the COVID-19 epidemic in Guangdong Province
29 April 2020
A new study led by researchers at Oxford and Guangdong Centre for Diseases Control and Prevention describes the epidemiology and genetic make-up of the COVID-19 outbreak in China’s most populous region, and shows how early and intensive testing and tracing helped to interrupt local transmission of the virus.
Global study to assess the effects of Covid-19 in pregnancy launched
29 April 2020
Researchers at the University of Oxford are today starting a large, international study to evaluate the effects of Covid-19 in pregnancy. The INTERCOVID study will provide women, families, health care providers and policy makers with high-quality evidence regarding the effects of Covid-19 in pregnancy on the health of the mother, fetus and newborn.
Government collaboration to track Covid-19 in UK population launched
24 April 2020
Researchers from the University of Oxford are supporting a new government study to track coronavirus (COVID-19) in the general population.
Oxford COVID-19 vaccine begins human trial stage
24 April 2020
University of Oxford researchers have begun testing a COVID-19 vaccine in human volunteers in Oxford today. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half (the control group) receiving a widely available meningitis vaccine.